SESSION 4: THERAPY Cancer Therapy 2003: Current State of the Century

Demetri, G.D. , M. von Mehren , C.D. Blanke , et al. (2002). “Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors.” N Engl J Med 347(7): 472—80.

Donehower, R.C. (1996). “The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute .” Stem Cells 14(1): 25—8.

Grunwald, V. and M. Hidalgo (2003). “Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment.” J Natl Cancer Inst 95(12): 851—67.

Hurwitz, H. , L. Fehrenbacher , T. Cartwright , et al. (××××) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Oral presentation, Proc ASCO, 39th Annual Meeting, Chicago, IL, Vol. 22 (abstract #3646).

Jemal, A. , T. Murray , A. Samuels , et al. (2003). Cancer statistics. CA Cancer J Clin 53(1): 5—26.

Mackie, T.R. , J. Kapatoes , K. Ruchala , et al. (2003). “Image Guidance for Precise Conformal Radiotherapy.” Int J Radiat Oncol Biol Phys 56(1): 89—105.

Manley, P.W. , G. Martiny-Baron , J.M. Schlaeppi , and J.M. Wood (2002). “Therapies Directed at Vascular Endothelial Growth Factor.” Expert Opin Investig Drug 11(12): 1715—36.

McMasters, K.M. , D.S. Reintgen , M.I. Ross , et al. (2001). “Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement.” J Clin Oncol 19(11): 2851—5.

O'Brien, S.G. , F. Guilhot , R.A. Larson , et al. (2003). “Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.” N Engl J Med 348(11): 994—1004.

Purdy, J.A. (2000). “Future Directions in 3-D Treatment Planning and Delivery: A Physicist's Perspective.” Int J Radiat Oncol Biol Phys 46(1): 3—6.

Schrag, D. , K.S. Panageas , E. Riedel , et al. (2003). “Surgeon Volume Compared to Hospital Volume as a Predictor of Outcome Following Primary Colon Cancer Resection .” J Surg Oncol 83(2): 68—78.

“ Stat Bite: Effect of Hospital Volume on Operative Mortality for Major Cancer Surgery.” (2003). J Natl Cancer Inst 95(10): 701.

Vogel, C.L. , M.A. Cobleigh , D. Tripathy , et al. (2002). “Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.” J Clin Oncol 20(3): 719—26.